About our research

Differentiation in human skin. Keratin 14 (red) marks basal epidermis, while Keratin 10 (green) marks differentiating supra-basal cells.

Maintaining proper tissue homeostasis involves careful regulation of cellular proliferation and survival in stem and transient amplifying cells. This is particularly true of the epidermis, which undergoes a constant process of proliferation, stratification, and differentiation. The epidermis is particularly susceptible to environmental damage, and unchecked proliferation of damaged cells can lead to cancer. Tumor suppressors such as p16INK4a and p53 serve the important function of causing growth arrest or apoptosis of damaged cells, but this has the unfortunate consequence of reducing normal tissue regenerative potential. In addition, there are many positive regulators of proliferation and stem cell function that when inappropriately activated can promote tumorigenesis. Thus, the combination of aberrant activation of normal growth regulators combined with the loss of tumor suppressors in epithelial tissues can lead to tumor development.

SCC cells expressing Keratin 14 (green) and Keratin 19 (red)

Squamous Cell Carcinoma (SCC) is a common cancer that develops in stratified epithelial tissues such as the epidermis, the oral cavity, and the lungs. The epidermis is the most common site of SCC, and cutaneous SCC that is not cured by surgery has few alternative treatments, resulting in approximately 9000 deaths per year.  In addition it has been difficult to identify cutaneous SCC tumors that will eventually recur and metastasize. SCC tumors found in the head & neck region and the lungs have much poorer prognosis, as surgical options are often limited. Despite intense study, there are still few effective treatments for SCC patients, in part due to the lack of molecular understanding of the disease.

Murine SCC tumor stained for p63 (red) and Smooth Muscle Actin (Green)

SCC stained for p63 (red) and Smooth Muscle Actin (Green)

The Ramsey laboratory is focused on exploring the mechanisms that drive SCC, in order to develop more targeted and effective therapies. Using tissue-specific activation of driving oncogenes combined with inactivation of tumor suppressors, we are working to develop pre-clinical SCC models that reflect genetic alterations found in Human SCC to test novel therapeutics and elucidate how specific alterations promote tumorigenesis. To complement this work, we have also developed a variety of biochemical systems to investigate the role of transcription factors and associated co-factors in driving SCC-specific transcription. These tools can be applied to study the large variety of transcription factors that contribute to the pathogenesis of SCC. Understanding the differences in transcriptional networks between normal and cancerous tissues will offer insight into the vulnerabilities of SCC tumors that can be therapeutically targeted to improve the survival and quality of life of patients.